Patrys Advances RLS-2202 Trial After Cohort One Passes Safety Review
PAB: $0.025 +0.00% · MC: $8M
Patrys completed dosing and follow-up for all participants in the first cohort of its Phase 1a RLS-2202 trial, and a post-quarter safety review recommended advancing to the next cohort. The company is targeting final participant dosing in the December quarter, subject to release of the clinical trial batch; it also agreed Yale will receive the deoxymab intellectual property, with Patrys entitled to half of Yale’s directly attributable commercialisation revenue. Patrys ended the quarter with approximately A$2 million in cash and anticipates an R&D tax incentive refund of approximately A$620,000.

Comments